Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board
May 01, 2024 04:00 ET
|
Tessellate Bio
AMSTERDAM and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment...
Tessellate BIO, an Emerging Precision Oncology Company, Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
November 15, 2023 03:00 ET
|
Tessellate Bio
AMSTERDAM and LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the...
Tessellate BIO Emerges from Stealth
October 17, 2023 03:00 ET
|
Tessellate Bio
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of...